6-(2-Methoxyphenyl)-1,3-dihydroindol-2-one → 3-{2-[6-(2-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-5-methyl-1H-pyrrol-3-yl}-propionic Acid
반응식
[CH3:1][O:2][C:3]1[CH:8]=[CH:7][CH:6]=[CH:5][C:4]=1[C:9]1[CH:17]=[C:16]2[C:12]([CH2:13][C:14](=[O:18])[NH:15]2)=[CH:11][CH:10]=1.[CH:19]([C:21]1[NH:22][C:23]([CH3:31])=[CH:24][C:25]=1[CH2:26][CH2:27][C:28]([OH:30])=[O:29])=O>>[CH3:1][O:2][C:3]1[CH:8]=[CH:7][CH:6]=[CH:5][C:4]=1[C:9]1[CH:17]=[C:16]2[C:12]([C:13](=[CH:19][C:21]3[NH:22][C:23]([CH3:31])=[CH:24][C:25]=3[CH2:26][CH2:27][C:28]([OH:30])=[O:29])[C:14](=[O:18])[NH:15]2)=[CH:11][CH:10]=1참가 물질
3
실험 절차
6-(2-Methoxyphenyl)-1,3-dihydroindol-2-one (71 mg, 0.3 mmol) was condensed with 3-(2-formyl-5-methyl-1H-pyrrol-3-yl)-propionic acid (54 mg) to give the title compound.
출처 및 근거
- ORD 기록
- ord-a99354a82d0e4540849157097c6fdb54
- 출처 데이터셋
- uspto-grants-2005_02